Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Hypothetical Scenario of an ATE Buyout
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Comment by Inthepezon Nov 19, 2020 7:46am
217 Views
Post# 31929184

RE:RE:Hypothetical Scenario of an ATE Buyout

RE:RE:Hypothetical Scenario of an ATE BuyoutFrom the article “Analysts have projected, if Zilretta is approved, that it could hit $500 to $600 million in peak”

meanwhile third party analysts project peak sales from only one IP (otena) to be ~$4 billion in peak sales for antibe. Yea, fundamentals are not just great, they’re epic, comparatively speaking. 

quote=IrishCanuck]There are a lot of Billions in this article from 2017 for osteoarthritis...

https://www.biospace.com/article/rumor-alert-sanofi-close-to-scooping-up-this-massachusetts-biotech-in-1-billion-deal-/

I dream of a 2 billion CAD minimum, for all three drugs and IP which is only 1.5 billion USD. Sometimes I think that's a lot and then I realize how much money is tossed aorund for nothing in the US. There are no rules to measure this, sometimes it's jsut a bidding war

[/quote]

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities